- Novartis (NYSE:NVS) Q3 results ($M): Total Revenues: 12,126 (-1.1%); Innovative Medicines: 8,173 (-1.0%); Alcon: 1,436 (-2.2%); Sandoz: 2,517 (-1.0%).
- Oncology: 3,235 (-6.2%); Ophthalmology: 1,370 (-0.2%); Est. Medicines: 1,121 (-17.5%); Neuroscience: 924 (+3.9%); Immunology & Dermatology: 770(+37.7%); Respiratory: 390 (+18.9%); Cardio-Metabolic: 363 (+22.2%).
- Net Income: 1,945 (+2.6%); EPS: 0.81 (+5.2%); CF Ops: 3,231 (+3.4%).
- Key Product Sales: Gleevec/Glivec: 834 (-29.6%); Gilenya: 790 (+13.5%); Lucentis: 456 (-6.0%); Tasigna: 441 (+6.0%); Sandostatin: 413 (-1.4%); Afinitor/Votubia: 393 (-5.1%); Galvus: 306 (+8.9%); Cosentyx: 301 (+242.0%).